卡培他滨联合多西紫杉醇节拍化疗治疗转移性乳腺癌临床研究

Clinical study of metastatic breast cancer treated with metronomic chemotherapy of capecitabine and docetaxel

目的探讨卡培他滨联合多西紫杉醇节拍化疗治疗转移性乳腺癌临床疗效与安全性。方法20例转移性乳腺癌病例,卡培他滨采用500 mg tid,连续口服第1-14天;国产多西紫杉醇25 mg.m^-2,静脉滴注持续1 h,第1、8 d给药。每21 d重复。结果20例中CR1例,PR11例,SD4例,PD4例,RR为60%（12/20）,DCR为80%（16/20）。不良反应为Ⅰ-Ⅱ度白细胞下降、关节肌肉酸痛及手足综合征,Ⅰ度消化道反应,Ⅲ度不良反应少见,无Ⅳ度不良反应。结论应用卡培他滨联合多西紫杉醇节拍化疗治疗转移性乳腺癌,具有疗效好、副作用小及患者依从性好等优点。

Aim To explore the efficacy and toxicity of metronomic chemotherapy of capecitabine and docetaxel for metastatic breast cancer（MBC）.Method 20 consecutive patients were treated with metronomic chemotherapy.Treatment consisted of docetaxel 25 mg·m^-2 on day 1 and 8 in combination with capecitabine 500mg thrice daily orally on days 1-14 of a 3-week cycle.Results Of 20 patients who received study treatment,1 had complete response（CR）,11 partial response（PR）,4 patients stable disease（SD）,and 4 patients had progressive disease（PD） ,for an overall response rate（ORR） of 60% and an disease control rate（DCR） of 80%. Toxicity was generally mild. Grade 1 or 2 toxicity included leucocytopenia, arthralgia/myalgia, nansea/vomiting and hand - foot syndrome. Grade 3 toxicity was very low. No Grade 4 toxicity was observed. Conclusion Using metronomic chemotherapy of capecitabine and docetaxel is an active combination in the treatment of patients with MBC. Toxicity with this schedule was manageable and minimal, making it an attractive regimen for further study.